Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.
Caris will be on the lookout for pancreatic cancer patients with low DNA mismatch repair protein expression.
There was a lot of growth in the precision medicine field in the past year, and some experts believe the FDA's decision to hold off on regulating LDTs could spur more innovation.
The assay will be designed to predict how pancreatic cancer patients respond to Threshold's investigational drug evofosfamide.
Caris Life Sciences also found that time-to-next treatment could be a surrogate endpoint for survival.
COTA, which also received funding from HealthScape Advisors, said it aims to reduce the amount of money wasted on unnecessary medical treatment.
Syapse is using the Series C funding to hire new staff and extend its Syapse Precision Medicine platform to support disease areas beyond cancer.
Members of Caris' Centers of Excellence for Precision Medicine Network will use the Syapse Precision Medicine Platform to merge data sets.
MedStar Health, which has 10 hospitals in Maryland and Washington DC, is now part of the Caris Centers of Excellence for Precision Medicine Network.
The firms will measure the health and economic impact of the Caris Molecular Intelligence panomic tumor profiling service for cancer patients.
Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.
People around the globe took to the streets to support science — some with signs.
Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.
In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.